Servatus’ research is directed at selectively improving specific characteristics of existing therapeutic proteins
Servatus has designed and produced modified derivatives with better solubility and half-life characteristics to cater to the growing market for therapeutic proteins with new modes of action.
Servatus focuses on proteins that have demonstrated clear clinical utility and data in human disease. Through rational redesign of key features, Servatus improves the protein’s bioavailability, half-life or biological potency.
Servatus applies state-of-the-art computation to design protein variants in silico to engineer improved characteristics with direct application to their clinical performance.
These protein variants are then rapidly cloned and expressed in amounts suitable for physico-chemical and pre-clinical assays. The assays screen for the most suitable protein variants to be tested in animal disease models prior to clinical testing to confirm their improved clinical utility.